drugset / Trial / NCT07045701
FMXIN002 in Patients at Risk of Anaphylaxis
RandomizedParallel-groupQuadruple-blindTreatment
Summary
Study Objective To evaluate the efficacy of FMXIN002, a powder-based intranasal epinephrine spray, for treating anaphylaxis. Study Design • Hypothesis: FMXIN002 will terminate anaphylactic reactions as effectively-or more rapidly-than IM epinephrine, as measured by clinical parameters.
Timeline
- Start
- 2025-06-12
- Primary completion
- 2026-06-12
- Completion
- 2026-07-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Epinephrine | Other / unclassified | 0.5 mg | Intranasal |
| Subject | Epinephrine | Other / unclassified | 4 mg | Intranasal |